Department of BIN Fusion Technology, Department of Polymer Nano Science & Technology, Chonbuk National University, Jeonju, South Korea (G.R., G.K., P.M.V.); and Key State Laboratory of Pharmaceutical Biotechnologies and Department of Pharmacology and Pharmacy, University of Hong Kong, Hong Kong SAR, People's Republic of China (P.M.V.)
Department of BIN Fusion Technology, Department of Polymer Nano Science & Technology, Chonbuk National University, Jeonju, South Korea (G.R., G.K., P.M.V.); and Key State Laboratory of Pharmaceutical Biotechnologies and Department of Pharmacology and Pharmacy, University of Hong Kong, Hong Kong SAR, People's Republic of China (P.M.V.).
J Pharmacol Exp Ther. 2015 Jan;352(1):14-22. doi: 10.1124/jpet.114.217935. Epub 2014 Oct 24.
Vanillin (VA) and vanillyl alcohol (VAA), components of natural vanilla, and ethyl vanillin (EtVA; synthetic analog) are used as flavoring agents and/or as additives by the food, cosmetic, or pharmaceutic industries. VA, VAA, and EtVA possess antioxidant and anti-inflammatory properties, but their vascular effects have not been determined. Therefore, we compared in isolated porcine coronary and basilar arteries the changes in isometric tension caused by VA, VAA, and EtVA. VA and its analogs caused concentration-dependent relaxations of both preparations during contractions from U46619 (9,11-dideoxy-11α,9α-epoxymethanoprostaglandin F2α, a thromboxane A2 receptor agonist), and of coronary arteries contracted with KCl or endothelin-1. The order of potency was VAA < VA < EtVA. The relaxations were not inhibited by endothelium removal, by inhibitors of NO synthases (N(ω)-nitro-l-arginine methyl ester hydrochloride), cyclooxygenases (indomethacin), soluble guanylyl cyclase (1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one [ODQ]), KCa (1-[(2-chlorophenyl)diphenylmethyl]-1H-pyrazole [TRAM-34], 6,12,19,20,25,26-hexahydro-5,27:13,18:21,24-trietheno-11,7-metheno-7H-dibenzo[b,n][1,5,12,16]tetraazacyclotricosine-5,13-diium ditrifluoroacetate hydrate [UCL-1684], or iberiotoxin), by KATP (glibenclamide), by Kir (BaCl2), by transient receptor potential receptor vanilloid 3 (TRPV3) channels (ruthenium red), or by antioxidants (catalase, apocynin, tempol, N-acetylcysteine, tiron). VA and its analogs inhibited contractions induced by Ca(2+) reintroduction in coronary arteries, and by an opener of L-type Ca(2+)-channels (methyl 2,6-dimethyl-5-nitro-4-[2-(trifluoromethyl)phenyl]-1,4-dihydropyridine-3-carboxylate [Bay K8644]) in coronary and basilar arteries. They inhibited contractions of coronary rings induced by the protein kinase C activator phorbol 12,13-dibutyrate to the same extent as the removal of extracellular Ca(2+) or incubation with nifedipine. Thus, in porcine arteries, relaxation from VA (and its analogs) is due to inhibition of L-type Ca(2+) channels. Hence, these compounds could be used to relieve coronary or cerebral vasospasms due to exaggerated Ca(2+) influx, but therapeutic efficacy would require exposures that far exceed the current levels obtained by the use of vanillin additives.
香草醛(VA)和香草醇(VAA)是天然香草的成分,乙基香草醛(EtVA;合成类似物)被食品、化妆品或制药行业用作调味剂和/或添加剂。VA、VAA 和 EtVA 具有抗氧化和抗炎特性,但它们的血管作用尚未确定。因此,我们在分离的猪冠状动脉和基底动脉中比较了 VA、VAA 和 EtVA 引起的等长张力变化。VA 和其类似物在 U46619(9,11-二去氧-11α,9α-环氧甲酰基前列腺素 F2α,血栓烷 A2 受体激动剂)引起的收缩期间以及 KCl 或内皮素-1 收缩的冠状动脉中引起浓度依赖性松弛。效力顺序为 VAA < VA < EtVA。松弛不受内皮去除、一氧化氮合酶抑制剂(N(ω)-硝基-L-精氨酸甲酯盐酸盐)、环氧化酶抑制剂(吲哚美辛)、可溶性鸟苷酸环化酶抑制剂(1H-[1,2,4]恶二唑[4,3-a]喹喔啉-1-酮[ODQ])、KCa(1-[[2-氯苯基]二苯甲基]-1H-吡唑[TRAM-34],6,12,19,20,25,26-六氢-5,27:13,18:21,24-三烯-11,7-亚甲-7H-二苯并[b,n][1,5,12,16]四氮杂环二十烷-5,13-二铵二水合物[UCL-1684]或 4-[[5-[[2-(三氟甲基)苯基]二苯甲基]-1H-吡唑并[3,4-d]嘧啶-4-基]氨基]-2-噻吩基]-2-(三氟甲基)苯甲酰胺)、KATP(格列本脲)、Kir(BaCl2)、瞬时受体电位香草醛 3 通道(钌红)或抗氧化剂(过氧化氢酶、白藜芦醇、叔丁基对苯二酚、N-乙酰半胱氨酸、钛铁试剂)的抑制。VA 和其类似物抑制冠状动脉中由 Ca2+再引入引起的收缩,以及由 L 型 Ca2+通道激动剂(5-硝基-4-[2-(三氟甲基)苯基]-2,6-二甲基-1,4-二氢吡啶-3-羧酸甲酯[Bay K8644])在冠状动脉和基底动脉中引起的收缩。它们抑制由蛋白激酶 C 激活剂佛波醇 12,13-二丁酸引起的冠状动脉环的收缩,其程度与去除细胞外 Ca2+或用硝苯地平孵育相同。因此,在猪动脉中,VA(及其类似物)的松弛是由于抑制了 L 型 Ca2+通道。因此,这些化合物可用于缓解由于 Ca2+内流过度引起的冠状动脉或脑血管痉挛,但治疗效果需要暴露于远远超过目前使用香草醛添加剂获得的水平。